
## Daniela Benati

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5553946/publications.pdf Version: 2024-02-01



DANIELA RENATI

#	Article	IF	CITATIONS
1	Engineered Sleeping Beauty Transposon as Efficient System to Optimize Chimp Adenoviral Production. International Journal of Molecular Sciences, 2022, 23, 7538.	4.1	0
2	Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model. American Journal of Human Genetics, 2021, 108, 295-308.	6.2	31
3	Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients. Journal of Experimental and Clinical Cancer Research, 2021, 40, 362.	8.6	18
4	CRISPR/Cas9 Gene Editing In Vitro and in Retinal Cells In Vivo. Methods in Molecular Biology, 2019, 1834, 59-74.	0.9	3
5	An Efficient <em>In Vitro</em> Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector. Journal of Visualized Experiments, 2018, , .	0.3	0
6	CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient. Molecular Therapy, 2018, 26, 2592-2603.	8.2	46
7	CD4 <sup>+</sup> T cell–mediated HLA class II cross-restriction in HIV controllers. Science Immunology, 2018, 3, .	11.9	54
8	DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers. Journal of Immunology, 2017, 199, 3437-3452.	0.8	7
9	MHC Class II Tetramer Labeling of Human Primary CD4+ T Cells from HIV Infected Patients. Bio-protocol, 2017, 7, e2187.	0.4	1
10	In vivo Editing of the Human Mutant Rhodopsin Gene by Electroporation of Plasmid-based CRISPR/Cas9 in the Mouse Retina. Molecular Therapy - Nucleic Acids, 2016, 5, e389.	5.1	147
11	Public T cell receptors confer high-avidity CD4 responses to HIV controllers. Journal of Clinical Investigation, 2016, 126, 2093-2108.	8.2	63
12	HIV Controllers Maintain a Population of Highly Efficient Th1 Effector Cells in Contrast to Patients Treated in the Long Term. Journal of Virology, 2012, 86, 10661-10674.	3.4	57